Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· November 10, 2025

Stocks Finish Sharply Higher on Plans to Reopen the US Government

View original at nasdaq.com
Stocks Finish Sharply Higher on Plans to Reopen the US Government The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.54%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.81%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.20%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Would give House lawmakers 36 hours' notice to return to the Capitol once the Senate passes the bill

    80% confidence
  • 82% of the S&P 500 companies that have reported so far have beaten forecasts, on course for the best quarter since 2021

    80% confidence
  • Q3 profits have risen 14.6% thus far, more than doubling expectations of 7.2% y/y

    80% confidence
  • So far, the effects of the tariffs have largely been confined to goods, with little spillover into services inflation or inflation expectations, which remain relatively well-anchored around our 2% target

    80% confidence
  • Expects a substantial rebound in the US economy in the first quarter, and there's limited room for further interest rate reductions without monetary policy becoming overly accommodative

    80% confidence
  • We see a labor market that's softening and wage growth that is moderating, so we don't want to make the mistake of holding on too long to high interest rates only to find out we've injured the economy

    80% confidence
  • The tariffs were an imposition of taxes on Americans, and that has always been the core power of Congress

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com